We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

IP Practice: Sidley Austin

Law360 (August 18, 2008, 12:00 AM EDT) -- The number of Hatch-Waxman Act-related lawsuits will likely drop over the next five years, but generic companies may start to challenge biotechnology patents, said the co-head of Sidley Austin's intellectual property practice group.

David Pritikin, who is a partner in Sidley Austin's Chicago office, predicted that the number of Hatch-Waxman cases will fall precipitously. “A lot of cases have already been brought and litigated,” he said. Meanwhile, the number of new drugs coming onto the market has ebbed over the past few years.

At the same...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.